NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dex in TIE NDMM
Updated: May 24, 2022
SABLe
NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)
An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group
Sponsor:
Ida Bruun Kristensen
Collaborators:
Karyopharm Therapeutics Inc
Odense Patient Data Explorative Network
Information provided by (Responsible Party):
Ida Bruun Kristensen, Odense University Hospital
ClinicalTrials.gov Identifier: NCT04717700
Official Title: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
First Posted : January 22, 2021
Click here to see details on ClinicalTrials.gov
Drug: Selinexor 20 MG Oral Tablet
Drug: Bortezomib Injection
Drug: Lenalidomide capsule
Drug: Dexamethasone Oral
Locations
Denmark
Estonia
Norway